Learn more about whether Biogen Inc. or Natera, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.
Biogen Inc. (NASDAQ:BIIB), a leading biopharmaceutical company specializing in neurology and rare diseases, finds itself at a critical juncture as it navigates a complex landscape of opportunities and ...
Court cites lack of inventiveness and failure to meet reproducibility standards | Decision part of broader international ...
Equities research analysts at Wedbush dropped their FY2024 EPS estimates for Biogen in a research report issued on Thursday, ...
Stock analysts at Wedbush lowered their Q4 2024 earnings estimates for Biogen in a research report issued on Thursday, January 23rd. Wedbush analyst L. Chico now forecasts that the biotechnology ...
The incidence of mental illness was higher among women with MS during both the prenatal period (incidence ratio [IR] 1.26, 95 ...
Ozanimodâ–¼ is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (RRMS) with active ...
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions ...
Biogen Pharmachem Industries Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/02/2025 ,inter alia, to consider and approve Pursuant to Regulation 29 of ...
Humana Inc. fell short of pleading standards in its racketeering lawsuit against Biogen Inc. over its allegedly fraudulent ...
Failed to fetch dynamically imported module: https://ca.finance.yahoo.com/assets/_app/immutable/nodes/163.BZrKoyEC.js ...
Of the 24 drugs, three approvals deviated from the others -- aducanumab; the synthetic hormone hydroxyprogesterone caproate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback